Previsioni

Il prezzo obiettivo medio degli analisti è +21,02€ (+171,23%). La mediana è +21,02€ (+171,23%).

Acquista	20
Mantieni	6
Vendi	2

Notizie Vai al feed delle notizie

Prothena promotes Annie Kingston to chief strategy officer and Michael Isaacs to general counsel

Prothena has appointed Annie Kingston as chief strategy officer with immediate effect; Michael Isaacs will become general counsel and corporate secretary in June following the departure of Michael Malecek. Both will join the leadership team and report to CEO Gene Kinney; Kingston will lead growth strategy, and Isaacs will head the legal department. Prothena is a late-stage clinical biotech company with programs targeting Parkinson’s, ATTR amyloidosis, Alzheimer’s and ALS and a market capitalization of about $566 million. » Altro su de.investing.com
Prothena launches $100 million share buyback program

Prothena’s board has approved a repurchase program to buy up to $100 million of its common stock. As of December 31, 2025, the biotech had cash of $308.4 million and no debt; without buybacks Prothena expects to have about $255 million in cash at the end of 2026. Potential clinical milestone payments of up to $105 million from partners (including Novo Nordisk and Bristol Myers Squibb) are not included in this forecast. The program runs through December 31, 2026, can be suspended at any time, and is intended to be executed in a market‑compliant manner under Rule 10b‑18 or via 10b5‑1 plans. » Altro su de.investing.com
Prothena: board member Paula Cobb leaves board for COO post at Manifold Bio

Paula Cobb is stepping down from Prothena’s board after six years to assume the role of chief operating officer (COO) at Manifold Bio. After her departure, Prothena’s board will consist of eight members. Prothena is a late-stage clinical biotechnology company with programs for ATTR amyloidosis, Alzheimer’s and Parkinson’s; analysts have recently cited price targets between $8 and $36. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Prothena Co. ha registrato ricavi pari a 884,97k€ e un utile netto di −16,28M€

(EUR)	giu 2026	YoY
Ricavi	+884,97k	76,40%
Utile lordo	+884,97k	76,40%
Utile netto	−16,28M	84,74%
EBITDA	−15,95M	63,70%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+423,20M€
Numero di azioni	52,35M
Massimo/minimo a 52 settimane	+10,13€ - +6,63€
Dividendi	No
Beta	-0,35
Rapporto P/E	−11,35
Rapporto PEG	−0,06
Rapporto P/B	+1,71
Rapporto P/S	+9,04

Profilo aziendale

Prothena Corporation plc, ein klinisches Unternehmen im Spätstadium, konzentriert sich auf die Entdeckung und Entwicklung neuartiger Therapien für lebensbedrohliche Krankheiten in den Vereinigten Staaten. Das Unternehmen ist an der Entwicklung von Birtamimab beteiligt, einem humanisierten Antikörper, der sich in einer klinischen Phase-III-Studie zur Behandlung von AL-Amyloidose befindet; Prasinezumab, einem humanisierten monoklonalen Antikörper, der sich in einer klinischen Phase-IIb-Studie zur Behandlung der Parkinson-Krankheit befindet; PRX004, das die klinische Phase-I-Studie zur Behandlung von Transthyretin-Amyloidose abgeschlossen hat; und PRX005, das sich in einer klinischen Phase-I-Studie zur Behandlung der Alzheimer-Krankheit befindet. Zu den Forschungs- und präklinischen Programmen des Unternehmens gehören PRX012 zur Behandlung der Alzheimer-Krankheit und ein dualer Aß-Tau-Impfstoff zur Behandlung und Prävention der Alzheimer-Krankheit. Prothena Corporation plc hat eine Lizenz-, Entwicklungs- und Vermarktungsvereinbarung mit F. Hoffmann-La Roche Ltd. und Hoffmann-La Roche Inc. zur Entwicklung und Vermarktung von Antikörpern, die auf Alpha-Synuclein abzielen, sowie eine Kooperationsvereinbarung mit Bristol-Myers Squibb zur Entwicklung von Antikörpern. Das Unternehmen wurde im Jahr 2012 gegründet und hat seinen Sitz in Dublin, Irland.

Nome	Prothena Co.
CEO	Gene G. Kinney
Sede centrale	Dublin, du Stati Uniti
Sito web	prothena.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	18/12/2012
Dipendenti	67